HUTCHMED (China) Limited (NASDAQ:HCM) Short Interest Update

HUTCHMED (China) Limited (NASDAQ:HCM - Get Free Report) saw a large decline in short interest during the month of January. As of January 15th, there was short interest totalling 412,700 shares, a decline of 12.5% from the December 31st total of 471,700 shares. Based on an average daily volume of 78,100 shares, the days-to-cover ratio is currently 5.3 days.

Hedge Funds Weigh In On HUTCHMED

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Jane Street Group LLC grew its stake in shares of HUTCHMED by 362.2% in the 3rd quarter. Jane Street Group LLC now owns 62,997 shares of the company's stock valued at $1,305,000 after buying an additional 49,366 shares during the period. State Street Corp grew its position in HUTCHMED by 0.9% in the third quarter. State Street Corp now owns 349,524 shares of the company's stock worth $6,826,000 after acquiring an additional 3,078 shares during the period. Crossmark Global Holdings Inc. raised its position in HUTCHMED by 10.7% in the fourth quarter. Crossmark Global Holdings Inc. now owns 18,591 shares of the company's stock valued at $268,000 after purchasing an additional 1,799 shares during the period. M&G PLC raised its position in HUTCHMED by 98.1% in the third quarter. M&G PLC now owns 267,231 shares of the company's stock valued at $5,345,000 after purchasing an additional 132,333 shares during the period. Finally, Blue Trust Inc. grew its holdings in shares of HUTCHMED by 638.2% during the 3rd quarter. Blue Trust Inc. now owns 3,536 shares of the company's stock worth $69,000 after purchasing an additional 3,057 shares during the period. Institutional investors and hedge funds own 8.82% of the company's stock.

HUTCHMED Stock Performance

Shares of HUTCHMED stock traded up $0.31 on Tuesday, hitting $13.52. 28,439 shares of the company were exchanged, compared to its average volume of 86,193. The company has a current ratio of 2.81, a quick ratio of 2.68 and a debt-to-equity ratio of 0.07. The company has a 50-day moving average price of $15.03 and a 200 day moving average price of $17.29. HUTCHMED has a 1-year low of $11.93 and a 1-year high of $21.92.

Wall Street Analyst Weigh In

Separately, StockNews.com cut shares of HUTCHMED from a "buy" rating to a "hold" rating in a research report on Monday, November 18th.

About HUTCHMED

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.